Benzudiazepine compound
Abstract
This record has no abstract on file.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
3 claims: 1 independent, 2 dependent
- 1Patentkrav 1. Sätt att framställa nya, farmaceutlskt aktiva föreningar med den allmänna formeln vari Y är väte, klor, brom, nitro, trifluormetyl eller metylsulfonyl, R lägre alkyl, R 1 hydroxi eller lägre alkoxi och Ar fenyl, tienyl ell fenyl substituerad med klor, fluor eller trifluormetyl, kännetecknat av att en förening med den allmänna formeln II N-alkyleringsmedel till att bilda den motsvarande 1-lägre alkylföreningen.
- 2Sätt enligt krav 1, kännetecknat av att föreningen aed den allmänna formeln (II) behandlas med ett alkali och med dimetylsulfat, dietylsulfat eller metyljodid.
- 3Sätt enligt krav 1 eller 2, kännetecknat av att 7-klor-3-hydroxi-5-fenyl-l,3-dihydro-2H-l,4-bensodiazepin-2-on metyleras till att bilda 7-klor-l,3-dihydro-3-hydroxi-l-metyl-?-fenyl-2H-l,^-bensodiazepln-2-on.
Independent claims3
43 paragraphs in 5 sections, as filed
SWEDEN
<img file="SE337033B_D0001.tif" />
PATENTS AND REGISTRATION OFFICE
PUBLISHING WRITING No. 337 033 int c. C 07 d 53/06 κι. 12 p 10/01
Patent Application. No 16452/67 Received on 29 X1 1967 Validity Day on 29 VIII 1962
Ans. generally available on 1 γΐχ · -j 968
Ans. published and the pamphlet published on the 26 th of 1971
Priority requested from 29 VIII 1961 ooh
III 1962 (USA, 154,569,177,174)
AMERICAN HOME PRODUCTS CORPORATION, NEW YORK, NY USA
Inventor »SC Bell
Ombuds PU PU
Process for Preparation of 3- (Hydroxy or Alkoxy) Substituted 1,4-Benzodiazepine * 2-ones
T '*.
Γ
The invention relates to the preparation of hitherto unknown 3-hydroxy-2H-1,4-benzodiazepin-2-ones having valuable effects on the central nervous system.
. The compounds obtained by the method according to the invention can be thundered by the formula
<img file="SE337033B_D0002.tif" />
wherein Ϊ is hydrogen, chlorine, bromine, nitro, trifluoromethyl or methylsalphonyl, R is lower alkyl, R ^ hydroxy or lower alkoxy and Ar is phenyl, thienyl or phenyl substituted with chlorine, fluorine or trifluoromethyl.
Preferably, R is methyl, R 2 hydroxy, Ar phenyl or chlorophenyl and a chloro substituent at the 7-position.
The compound of general formula I has valuable anticonvulsant and anti-masking effects. Some of them have sedative effects and some have tranquilizing effects without being sedative. Some of them have valuable drug-inhibiting effects and raise libido.
IN <sup>r</sup> The compounds of general formula I can be prepared by a method characterized essentially by reacting an N-alkylating agent containing a lower alkyl group with a benzodiazepine of the general formula
K.
<sup>c</sup> L
-<<sub>C</sub>/<sup>hrs </sup>R<sup>1</sup>
II where R<sup>1</sup>, Y and Ar are as defined above to form a 1-lower alkyl compound.
Generally, the compound of formula II is treated with an alkaline substance (e.g., sodium or potassium hydroxide) and then with, for example, dimethyl sulfate, diethyl sulfate or methyl iodide.
The starting materials of general formula II, which contain a hydrogen atom at the 1-position, can be prepared by hydrolyzing or alcoholizing a compound of the general formula
<img file="SE337033B_D0003.tif" />
III o
where Y and Ar represent the same as above and R represents an acyloxy radical or a halogen atom. The compounds of general formula 2
III, where R is a halogen atom, can be prepared by producing a 5- & aryl-1,3-dihydro-2H-1,4-benzodiazepin-2-one-h-oxide of the general formula
hrs
IN
<img file="SE337033B_D0004.tif" />
IV where Y and Ar represent the same as above, reacting with an alkyl haloformate (cf. Patent 323 O8) the compounds of general formula III wherein R is a carboxylic acyloxy radical can be prepared by acylating a compound of general formula IV a carboxylic acid halide or anhydride (cf. patent 322 22?).
The products of the invention may be administered parenterally or orally, and may, as desired, be combined with pharmaceutically acceptable diluents, solvents, suspending agents, carriers, fillers, excipients, binders, dyes and flavors, etc. to produce suitable dosage forms.
The following examples illustrate the invention.
Example 1
A mixture of 3.4 g of 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 4 ml of 4-N sodium hydroxide and 1.4 ml dimethyl sulfate in 200 ml of 50% alcohol was stirred for 2 hours and then evaporated in vacuo to dryness. Water and ether were added and the ether layer separated. The solvent was removed and the residue was recrystallized from cyclohexane to give 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. Mp: 119121 ° C.
Example 2
7-Chloro-5- (o-chlorophenyl) -1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one was prepared from 7 “chloro-5- (o-chlorophenyl) -1,3-dihydrp-3-hydroxy-2H-1,4-benzodiazepin-2-one according to the procedure described in Example 1. mp .; 192-194- ° C.
<sup>C</sup>16<sup>hrs</sup>12<sup>C1</sup>2<sup>N</sup>2°2<sup>S Estimated! c</sup> 57.33 H 3.61 N 8.36 Cl $ 21.15
Found; C 57.4-2 H 3.44 N 8.69 Cl $ 21.25
Example 3 1-Cyclopropylmethyl-7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine “2” One at m.p. 3 'dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one according to the procedure described in Example 1, but using a cyclopropylmethyl bromide.
Example 4X-methyl-7-chloro-1,3 'dihydro-3-methoxy-5-phenyl-2H-1,4-benzodiazepin-2-one, m.p. chloro-1,3 'dihydro-3-methoxy-5-phenyl-2H-1,4-benzodiazepin-2-one according to the procedure described in Example 1.
Example 5
1-methyl-7-chloro, 3-dihydro-3-methoxy-5- (o-chloro or enyl) -2H-1,4-benzodiazepin-2-one, m.p. 4- ° C can be prepared from 7-chloro-1,3-dihydro-3'-methoxy-5- (o-chlorophenyl) -2H-1,4-benzodiazepin-2-one according to the procedure described in Example 1.
Contents5
145 members in 20 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 13456961 | United States of America | A | |
| 17717462 | United States of America | A | |
| 37974064 | United States of America | A |
Members145
| Document | Office | Kind | |
|---|---|---|---|
| BE621819A | Belgium | A | |
| BE656606A | Belgium | A | |
| NL134421C | Netherlands (Kingdom of the) | C | |
| NL298071A | Netherlands (Kingdom of the) | A | |
| NL301733A | Netherlands (Kingdom of the) | A | |
| ES280170A1 | Spain | A1 | |
| ES291045A2 | Spain | A2 | |
| FR2217M | France | M | |
| ES294651A1 | Spain | A1 | |
| BE641547A | Belgium | A | |
| ES306938A1 | Spain | A1 | |
| NL6414066A | Netherlands (Kingdom of the) | A | |
| US3197467A | United States of America | A | |
| ES314791A1 | Spain | A1 | |
| BE666274A | Belgium | A | |
| LU48964A1 | Luxembourg | A1 | |
| NL6508496A | Netherlands (Kingdom of the) | A | |
| GB1021381A | United Kingdom | A | |
| GB1021382A | United Kingdom | A | |
| GB1022642A | United Kingdom | A | |
| GB1022643A | United Kingdom | A | |
| GB1022644A | United Kingdom | A | |
| GB1022645A | United Kingdom | A | |
| FR1437388A | France | A | |
| FR1438078A | France | A | |
| US3257382A | United States of America | A | |
| GB1034872A | United Kingdom | A | |
| GB1035174A | United Kingdom | A | |
| FR1444689A | France | A | |
| CH417611A | Switzerland | A | |
| US3296249A | United States of America | A | |
| US3313805A | United States of America | A | |
| CY386A | Cyprus | A | |
| CH438337A | Switzerland | A | |
| DK107811C | Denmark | C | |
| GB1078788A | United Kingdom | A | |
| GB1082212A | United Kingdom | A | |
| GB1082213A | United Kingdom | A | |
| US3344136A | United States of America | A | |
| CH446362A | Switzerland | A | |
| AT258922B | Austria | B | |
| US3365485A | United States of America | A | |
| AT259561B | Austria | B | |
| CH451173A | Switzerland | A | |
| CH451519A | Switzerland | A | |
| US3384660A | United States of America | A | |
| US3395181A | United States of America | A | |
| US3401200A | United States of America | A | |
| IL22545A | Israel | A | |
| CH466297A | Switzerland | A | |
| CH467790A | Switzerland | A | |
| DE1445467A1 | Germany | A1 | |
| DE1445424A1 | Germany | A1 | |
| DE1445412A1 | Germany | A1 | |
| CH468973A | Switzerland | A | |
| CH468974A | Switzerland | A | |
| CH469013A | Switzerland | A | |
| US3435005A | United States of America | A | |
| CH471136A | Switzerland | A | |
| IL23813A | Israel | A | |
| SE310884B | Sweden | B | |
| DE1295563B | Germany | B | |
| DE1445420A1 | Germany | A1 | |
| CY498A | Cyprus | A | |
| DK114514B | Denmark | B | |
| DE1300114B | Germany | B | |
| DK114836B | Denmark | B | |
| SE314680B | Sweden | B | |
| US3468878A | United States of America | A | |
| DE1543325A1 | Germany | A1 | |
| SE316187B | Sweden | B | |
| AT275867B | Austria | B | |
| SE317978B | Sweden | B | |
| MY6900102A | Malaysia | A | |
| MY6900345A | Malaysia | A | |
| DE1645903A1 | Germany | A1 | |
| DE1570365A1 | Germany | A1 | |
| CH486469A | Switzerland | A | |
| SE322225B | Sweden | B | |
| DE1545555A1 | Germany | A1 | |
| SE323080B | Sweden | B | |
| OA02171A | African Intellectual Property Organization (OAPI) | A | |
| DE1645904B1 | Germany | B1 | |
| DE1645920A1 | Germany | A1 | |
| US3547993A | United States of America | A | |
| DE1570365B2 | Germany | B2 | |
| MY7000021A | Malaysia | A | |
| DK120492B | Denmark | B | |
| SE335734B | Sweden | B | |
| SE337033BThis record | Sweden | B | |
| DE1795558A1 | Germany | A1 | |
| DE1795556A1 | Germany | A1 | |
| DE1793259A1 | Germany | A1 | |
| DE1795553A1 | Germany | A1 | |
| SE343061B | Sweden | B | |
| DE1795231A1 | Germany | A1 | |
| DE1795509A1 | Germany | A1 | |
| DE1795511A1 | Germany | A1 | |
| FI46072B | Finland | B | |
| FI46385B | Finland | B |
Numbers
- Application
- 1643267
Classification
- CPC, 7
- C07D409/04
- C07D213/50
- C07D307/46
- C07D333/22
- C08G2/06
- C08G2/18
- C08G2/22
- IPC, 6
- C07D213 50
- C07D243 26
- C07D307 46
- C07D333 22
- C07D409 04
- C08G2 00